Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04171791 · ClinicalTrials.gov registry record · Phase 1
A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)
A Phase 1 study of CTCL, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT04171791 is a Phase 1 study of CTCL that has completed, run by Yale University. The registered enrollment target is 4 participants, below the 76-participant average among 4 other CTCL trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04171791, a Phase 1 study of CTCL, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study are to evaluate the safety and tolerability of ABT-199 (venetoclax) in patients with advanced Cutaneous T cell lymphoma (CTCL). A secondary objective is to explore clinical response to ABT-199 (venetoclax) in patients with advanced CTCL.
Conditions Studied
Interventions
- DRUG ABT-199 (venetoclax)
Study Locations (1)
Connecticut
- Yale New Haven Hospital / Smilow Cancer Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2020-01-15 |
| Est. Completion | 2021-06-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04171791
The ClinicalTrials.gov registry entry for NCT04171791 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 76-participant average among 4 other CTCL trials with a reported enrollment target (95% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with CTCL appearing as the primary indexed condition, and to 1 intervention - of which ABT-199 (venetoclax) is the first listed.
NCT04171791 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT04171791 about?
NCT04171791 is a clinical study titled "A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)". The objective of this study are to evaluate the safety and tolerability of ABT-199 (venetoclax) in patients with advanced Cutaneous T cell lymphoma (CTCL). A secondary objective is to explore clinical response to ABT-199 (venetoclax) in patients with advanced CTCL.
What is the current status of trial NCT04171791?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2020-01-15. Estimated completion is 2021-06-22.
What conditions does trial NCT04171791 study?
This clinical trial studies the following conditions: CTCL.
What interventions are being tested in trial NCT04171791?
The interventions under investigation include: ABT-199 (venetoclax) (DRUG).
Who is sponsoring clinical trial NCT04171791?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04171791 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CTCL
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
ACTIVE NOT RECRUITING · Phase 1
-
StrataCTX® as a Steroid Sparing Device
RECRUITING · NA
-
Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL
RECRUITING · Phase 3
-
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.